Put Options

16 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.96 - $27.6 $1.89 Million - $2.37 Million
85,900 New
85,900 $2.23 Million
Q1 2022

May 17, 2022

BUY
$17.03 - $22.67 $1.13 Million - $1.51 Million
66,500 Added 36.66%
247,900 $5.62 Million
Q4 2021

Feb 15, 2022

BUY
$15.84 - $21.88 $269,280 - $371,960
17,000 Added 10.34%
181,400 $3.32 Million
Q3 2021

Nov 16, 2021

SELL
$16.3 - $21.14 $404,240 - $524,272
-24,800 Reduced 13.11%
164,400 $3.48 Million
Q2 2021

Aug 16, 2021

BUY
$17.95 - $25.56 $2.63 Million - $3.74 Million
146,400 Added 342.06%
189,200 $3.45 Million
Q1 2021

May 18, 2021

SELL
$20.53 - $25.22 $572,787 - $703,638
-27,900 Reduced 39.46%
42,800 $967,000
Q4 2020

Feb 17, 2021

BUY
$18.39 - $24.8 $226,197 - $305,040
12,300 Added 21.06%
70,700 $1.42 Million
Q3 2020

Nov 17, 2020

SELL
$20.67 - $26.94 $169,494 - $220,908
-8,200 Reduced 12.31%
58,400 $1.43 Million
Q2 2020

Aug 17, 2020

BUY
$16.46 - $27.42 $683,090 - $1.14 Million
41,500 Added 165.34%
66,600 $1.58 Million
Q3 2019

Nov 14, 2019

BUY
$17.68 - $22.65 $102,544 - $131,370
5,800 Added 30.05%
25,100 $444,000
Q2 2019

Aug 15, 2019

SELL
$18.93 - $24.75 $117,366 - $153,450
-6,200 Reduced 24.31%
19,300 $412,000
Q1 2019

May 16, 2019

SELL
$19.6 - $24.76 $154,840 - $195,604
-7,900 Reduced 23.65%
25,500 $607,000
Q2 2018

Aug 15, 2018

SELL
$18.56 - $22.45 $703,424 - $850,855
-37,900 Reduced 53.16%
33,400 $719,000
Q1 2018

May 15, 2018

BUY
$22.15 - $31.89 $405,345 - $583,587
18,300 Added 34.53%
71,300 $1.58 Million
Q4 2017

Feb 15, 2018

SELL
$24.23 - $30.93 $72,690 - $92,790
-3,000 Reduced 5.36%
53,000 $1.61 Million
Q3 2017

Nov 14, 2017

BUY
$23.35 - $29.24 $1.31 Million - $1.64 Million
56,000
56,000 $1.36 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.